Medical Pharmacology: Chapter 23: Ergot Alkaloid Pharmacology -- Module 2: Ergotamine and Dihydroergotamine in Migraine Management

Chapter 23: Ergot Alkaloid Pharmacology — Module 2: Ergotamine and Dihydroergotamine in Migraine Management
Tier: Clinical Vignette (11 questions)

1. A 41-year-old man with episodic migraine takes ergotamine-caffeine (Cafergot) for acute attacks. He was started on ketoconazole (an azole antifungal) 5 days ago for a nail fungal infection by his dermatologist, who was unaware of his ergotamine use. He now presents to urgent care with bilateral burning leg pain, cold feet, and mottled skin on both lower extremities. Pedal pulses are absent by palpation and confirmed absent by Doppler. Which of the following correctly identifies the mechanism of his presentation and the most important immediate intervention?

A) He has developed serotonin syndrome from the combination of ketoconazole and ergotamine, since ketoconazole inhibits serotonin reuptake transporters in peripheral neurons; the most important immediate intervention is cyproheptadine (a 5-HT2A antagonist) administered orally to reduce serotonergic excess in peripheral vascular tissue
B) He has developed an idiosyncratic allergic vasculitis from ketoconazole that is coincidental to his ergotamine use; ketoconazole is a known cause of small-vessel immune complex deposition in the lower extremity vasculature, and the most important immediate intervention is high-dose intravenous corticosteroids to suppress the immune complex-mediated inflammation
C) He has developed peripheral arterial thromboembolism from ketoconazole-induced platelet aggregation; ketoconazole inhibits prostacyclin synthesis in vascular endothelium by blocking CYP3A4-dependent arachidonic acid metabolism, shifting the thromboxane-prostacyclin balance toward platelet aggregation, and the most important immediate intervention is emergency anticoagulation with intravenous heparin
D) He has developed gangrenous ergotism precipitated by ketoconazole-mediated CYP3A4 inhibition — ketoconazole is a potent CYP3A4 inhibitor that blocks ergotamine's primary metabolic clearance pathway, dramatically elevating ergotamine plasma concentrations to toxic levels; the most important immediate interventions are stopping both ergotamine and ketoconazole and initiating vasodilatory therapy with IV nitroprusside and/or IV prostaglandin E1 (alprostadil) with anticoagulation
E) He has developed Raynaud phenomenon exacerbated by ketoconazole through a pharmacodynamic interaction at alpha-2 adrenergic receptors; ketoconazole potentiates alpha-2-mediated digital vasoconstriction by inhibiting the phosphodiesterase enzyme that normally limits cyclic AMP-mediated vasodilation, and the most important immediate intervention is a calcium channel blocker such as nifedipine

ANSWER: D

Rationale:

This question asked you to identify the mechanism of this patient's presentation and the correct immediate management. He has developed gangrenous ergotism. The mechanism is a CYP3A4 pharmacokinetic drug interaction: ketoconazole is a potent CYP3A4 inhibitor, and CYP3A4 is the primary enzyme responsible for ergotamine's pre-systemic and hepatic first-pass metabolism. When CYP3A4 is inhibited by ketoconazole, ergotamine plasma concentrations rise dramatically — case reports document levels 10–40 times the normal therapeutic range — producing severe peripheral vasoconstriction through combined alpha-adrenergic and 5-HT2A receptor activation. The bilateral presentation (burning leg pain, cold mottled feet, absent pulses) is classic for ergotism. Azole antifungals (ketoconazole, itraconazole, fluconazole, voriconazole) are among the most potent CYP3A4 inhibitors relevant to ergot-prescribing contexts, and their co-administration with ergotamine or DHE is absolutely contraindicated by FDA labeling. Immediate management requires stopping both drugs and initiating vasodilatory therapy: IV nitroprusside (acting via nitric oxide downstream of both alpha-adrenergic and 5-HT2A receptor activation) and/or IV prostaglandin E1 (alprostadil, acting via prostanoid receptors) with heparin anticoagulation to prevent secondary in situ thrombosis in the ischemic vessels.

Option A: Option A is incorrect — ketoconazole is not a serotonin reuptake transporter inhibitor, and this presentation is not serotonin syndrome. Serotonin syndrome produces a triad of neuromuscular abnormalities, autonomic instability, and altered mental status — not the isolated bilateral lower extremity ischemia with absent pulses described here. This presentation is a peripheral vascular emergency, not a neurotoxic syndrome.
Option B: Option B is incorrect — ketoconazole does not cause immune complex vasculitis affecting lower extremity small vessels as a drug-specific toxicity. The presentation is not coincidental to ergotamine use; the bilateral vascular occlusion is mechanistically explained by the ketoconazole-ergotamine CYP3A4 interaction, and corticosteroids are not the treatment for ergot-induced vasospasm.
Option C: Option C is incorrect — ketoconazole does not inhibit prostacyclin synthesis through CYP3A4-dependent arachidonic acid metabolism in a way that causes arterial thromboembolism at standard antifungal doses. The mechanism of this patient's bilateral ischemia is ergotamine plasma concentration elevation from CYP3A4 inhibition, not a ketoconazole-induced prostacyclin-thromboxane imbalance.
Option E: Option E is incorrect — this presentation is not Raynaud phenomenon and ketoconazole does not cause pharmacodynamic potentiation of alpha-2 adrenergic vasospasm through phosphodiesterase inhibition. Raynaud phenomenon causes episodic, reversible color changes in fingers (white-blue-red) triggered by cold or stress; this patient has acute bilateral limb-threatening ischemia with absent Doppler signals, which is gangrenous ergotism requiring emergent vasodilatory therapy.

2. A 34-year-old woman with episodic migraine and Raynaud phenomenon — a condition characterized by episodic vasospasm of digital arteries producing color changes (white, then blue, then red) in her fingers and toes triggered by cold or stress — asks her neurologist whether ergotamine would be appropriate for her migraines. She notes that her Raynaud episodes have been relatively infrequent and mild, and she wonders whether her vascular condition is relevant to the migraine medication choice. Which of the following is the correct response?

A) Ergotamine is absolutely contraindicated in this patient because Raynaud phenomenon represents a vascular territory where blood flow is already episodically compromised by vasospasm; ergotamine's combined alpha-adrenergic and serotonergic vasoconstrictive activity could reduce digital perfusion to the point of ischemia or infarction, and the severity or frequency of Raynaud episodes does not affect this contraindication status
B) Ergotamine may be used cautiously in this patient provided she takes it only at the onset of migraine attacks rather than during Raynaud episodes, since the temporal separation of the two conditions means that ergotamine's vasoconstrictive effect on digital vessels will have resolved before the next Raynaud episode is triggered by cold exposure
C) Ergotamine is relatively — but not absolutely — contraindicated in Raynaud phenomenon; low-dose ergotamine (0.5 mg per attack) may be used if she wears gloves and avoids cold exposure for 24 hours after each dose to prevent the cold-triggered Raynaud vasospasm that would combine with residual ergotamine-induced tone to produce digital ischemia
D) Ergotamine is safe in this patient because Raynaud phenomenon affects digital arterioles, which express primarily alpha-2 adrenergic receptors mediating cold-triggered vasospasm, while ergotamine's cranial vasoconstrictive effect is mediated by 5-HT1B receptors expressed on intracranial vessels but not on peripheral digital arterioles — making the drug selective for the cranial circulation at therapeutic doses
E) Ergotamine is safe if she pre-treats with a calcium channel blocker (nifedipine 10 mg) before each ergotamine dose, since nifedipine's direct smooth muscle vasodilatory effect in digital vessels will counteract any ergotamine-mediated digital vasoconstriction while leaving the cranial vasoconstrictive antimigraine effect intact

ANSWER: A

Rationale:

This question asked you to apply the absolute cardiovascular contraindications of ergotamine to a patient with Raynaud phenomenon. Raynaud phenomenon is an absolute contraindication to ergotamine and DHE. The mechanistic basis is shared with all absolute cardiovascular contraindications: ergotamine's combined alpha-adrenergic and serotonergic (5-HT2A-mediated) vasoconstrictive activity reduces perfusion in peripheral vascular beds; in a patient with Raynaud phenomenon, digital arteries are already subject to episodic vasospasm that reduces or eliminates digital perfusion. Adding ergotamine's vasoconstrictive pharmacology to this baseline vulnerability can precipitate digital ischemia, infarction, or gangrene. The severity or frequency of the patient's Raynaud episodes is clinically irrelevant to the contraindication status — even mild or infrequent Raynaud phenomenon constitutes an absolute contraindication because the risk of catastrophic digital ischemia is not proportional to baseline episode frequency or severity.

Option B: Option B is incorrect — temporal separation of ergotamine use from Raynaud episodes does not eliminate the risk. Ergotamine has a beta-phase half-life of approximately 21 hours and active vasoconstrictive metabolites that sustain pharmacodynamic effects for 24 hours or more after a dose; residual ergotamine and metabolite activity persists well into the period between migraine treatment and the next potential Raynaud trigger, and there is no safe window created by temporal separation.
Option C: Option C is incorrect — there is no established safe low-dose threshold for ergotamine use in Raynaud phenomenon, and behavioral modifications (gloves, cold avoidance) do not alter the contraindication status. Stating this as a relative rather than absolute contraindication understates the established prescribing guidance; Raynaud phenomenon is listed as an absolute contraindication in ergotamine prescribing information.
Option D: Option D is incorrect — ergotamine is not a selective cranial vasoconstrictive agent. Its alpha-adrenergic and 5-HT2A receptor activity produces peripheral vasoconstriction in digital and limb vasculature as well as cranial vasoconstriction. Digital arterioles express alpha-adrenergic receptors that ergotamine activates; the drug's vasoconstrictive pharmacology is systemic, not cranially restricted.
Option E: Option E is incorrect — pre-treatment with nifedipine does not adequately counteract ergotamine's digital vasoconstrictive effects while preserving cranial antimigraine efficacy. There is no evidence base for this combination as a safe prescribing strategy in Raynaud patients, and the premise that cranial and digital vasoconstrictive effects can be pharmacologically dissociated by calcium channel blocker pretreatment is not supported by the established pharmacology of either drug.

3. A 27-year-old woman at 12 weeks gestation presents to her obstetrician's office with a severe migraine attack. She has a history of episodic migraine and used ergotamine-caffeine (Cafergot) effectively before her pregnancy. She asks whether she can take her usual ergotamine for this attack, reasoning that the first trimester is nearly over and that organogenesis is largely complete at 12 weeks. She has no other medical problems. Which of the following is the most accurate and complete response to her request?

A) Ergotamine may be used at this gestational age because the primary teratogenic risk from ergotamine — direct fetal organ malformation — occurs during the first 10 weeks of organogenesis; at 12 weeks, the structural development of major organs is complete and ergotamine's risk profile is similar to that of other vasoactive drugs used in pregnancy for severe migraine
B) Ergotamine may be considered with caution at doses below 1 mg per attack in the second trimester but remains contraindicated in the first trimester; since she is at the boundary between the first and second trimester at 12 weeks, the risk-benefit decision should be individualized based on migraine severity and functional impairment
C) Ergotamine is absolutely contraindicated throughout all trimesters of pregnancy, including at 12 weeks; the contraindication is not based on teratogenicity during organogenesis but on ergotamine's uterotonic effect on the myometrium and its vasoconstrictive reduction of uteroplacental blood flow, both of which can cause fetal harm — including spontaneous abortion, fetal hypoxia, and intrauterine growth restriction — at any gestational age
D) Ergotamine's contraindication in pregnancy applies specifically to the third trimester when uterotonic agents can precipitate preterm labor; at 12 weeks, the uterus is not yet sufficiently sensitive to ergotamine's oxytocic properties to pose a clinically significant risk, and a single dose for a severe attack is unlikely to cause harm
E) Ergotamine may be used once during this pregnancy if no other migraine treatment has provided relief, since case-control studies have not demonstrated a statistically significant association between first-trimester ergotamine use and adverse fetal outcomes when the drug was used at doses below 2 mg per attack; the teratogenic risk is theoretical rather than confirmed

ANSWER: C

Rationale:

This question asked you to correctly state ergotamine's contraindication status in pregnancy and its mechanistic basis. Ergotamine is absolutely contraindicated throughout all trimesters of pregnancy. The patient's reasoning — that organogenesis is complete at 12 weeks and therefore the teratogenic risk has passed — is based on a fundamental misunderstanding of why ergotamine is contraindicated. The contraindication is not primarily about structural teratogenicity during organogenesis. It is based on two ongoing pharmacological mechanisms that are active at any gestational age: first, ergotamine's direct uterotonic effect on the estrogen-primed myometrium, which stimulates uterine contractions capable of causing spontaneous abortion at any gestational age; second, its vasoconstrictive reduction of uteroplacental blood flow, which can cause fetal hypoxia and intrauterine growth restriction throughout pregnancy. Case reports document spontaneous abortion and fetal growth restriction associated with ergotamine use in the first trimester. The contraindication is not trimester-specific and is not mitigated by the completion of organogenesis.

Option A: Option A is incorrect — the rationale for ergotamine's pregnancy contraindication is not direct structural teratogenicity during organogenesis. The mechanisms of harm — uterotonic activity and uteroplacental vasoconstriction — persist at any gestational age, and describing the risk as similar to other vasoactive drugs at 12 weeks understates the absolute contraindication status.
Option B: Option B is incorrect — there is no established safe dose threshold for ergotamine in any trimester of pregnancy. Stating that doses below 1 mg may be considered in the second trimester is not supported by prescribing guidance or clinical evidence; the absolute contraindication applies without trimester-specific or dose-specific exceptions.
Option D: Option D is incorrect — the contraindication is not limited to the third trimester. Uterotonic sensitivity to ergotamine exists throughout pregnancy, not only when the uterus is near term; spontaneous abortion from ergotamine's uterotonic activity is a documented risk in the first trimester, not only preterm labor in the third.
Option E: Option E is incorrect — ergotamine's pregnancy contraindication is not contingent on case-control data demonstrating a statistically significant association with adverse outcomes. The absolute contraindication is based on the established pharmacological mechanisms (uterotonic activity, uteroplacental vasoconstriction) and documented case reports, and applies regardless of whether large epidemiological studies have produced a statistically significant signal.

4. A 45-year-old woman with a 15-year history of episodic migraine presents reporting that her headaches have become much more frequent over the past 8 months. She now has headache on approximately 22 days per month — a dull, persistent background headache most days and more severe attacks superimposed on this baseline. She uses ergotamine-caffeine (Cafergot) on approximately 10 days per month, stating that it is the only medication that provides any relief. She denies any new medications, systemic illness, or neurological symptoms. Neurological examination is normal. Which of the following best identifies her diagnosis and the most appropriate management approach?

A) She has developed chronic migraine from disease progression, which is a natural evolution in some patients with longstanding episodic migraine unrelated to medication use; she should be switched to a daily preventive agent such as topiramate, and her ergotamine use pattern need not be addressed since the medication has not caused the transformation
B) She has tension-type headache superimposed on her migraine, which has developed because ergotamine's alpha-adrenergic vasoconstrictive activity in cervical muscles produces chronic cervical muscle tension that generates daily non-migraine headache; the treatment is to stop ergotamine and begin physical therapy for cervical muscle dysfunction
C) She has ergotamine-induced rebound vasodilation: her daily background headache reflects the vascular rebound that occurs between ergotamine doses as the drug clears and the previously constricted vessels dilate; she should switch to a longer-acting vasoactive agent such as frovatriptan to prevent the rebound vasodilation between doses
D) She has ergotamine toxicity from cumulative vasoconstrictive damage to cerebral blood vessel walls; chronic ergotamine use at 10 days per month produces progressive cerebrovascular endothelial injury that leads to neurogenic inflammation and daily headache; the treatment is ergotamine discontinuation plus high-dose niacin to restore endothelial function
E) She has medication overuse headache (MOH) from ergotamine used at 10 days per month — at or above the ergotamine MOH threshold of 6–10 days per month — in which central sensitization and trigeminal 5-HT1B/1D receptor downregulation maintain daily headache; appropriate management requires initiating preventive migraine therapy to reduce attack frequency and managing the ergotamine withdrawal phase, since MOH will not resolve with ergotamine continuation regardless of dose adjustment

ANSWER: E

Rationale:

This question asked you to recognize medication overuse headache from ergotamine and identify the correct management. This patient has classic ergotamine-related MOH. The key diagnostic features are: a patient with established episodic migraine, escalating headache frequency over months to near-daily, ergotamine use at 10 days per month (at or above the ergotamine MOH threshold of 6–10 days per month), and a pattern of daily background headache with superimposed more severe attacks that are temporarily responsive to the overused medication. The mechanism is central sensitization and downregulation of trigeminal 5-HT1B/1D receptors from sustained overexposure to ergotamine's pharmacodynamic effects, driven by its long pharmacodynamic duration from active metabolites. Management requires two components: initiating preventive migraine therapy (beta-blockers, topiramate, valproate, or a CGRP-targeted monoclonal antibody) to reduce migraine attack frequency and thereby reduce the need for acute medication; and structured ergotamine withdrawal, since MOH does not resolve with continued ergotamine use regardless of dose reduction, and the sensitized state must be allowed to reverse through drug-free time.

Option A: Option A is incorrect — attributing her headache transformation to natural disease progression without addressing her medication use pattern is clinically incorrect. Medication overuse is the most common and treatable cause of new daily headache in a patient with prior episodic migraine, and the history of 10 days per month ergotamine use at or above the MOH threshold makes MOH the working diagnosis. Prescribing preventive therapy without addressing overuse typically fails because MOH prevents preventive agents from achieving their full efficacy.
Option B: Option B is incorrect — ergotamine does not cause chronic cervical muscle tension through alpha-adrenergic vasoconstrictive activity in cervical muscles as the mechanism of daily headache in this presentation. The established mechanism of ergotamine-related daily headache transformation is central sensitization and receptor downregulation through medication overuse, not peripheral muscle tension from cervical vasoconstriction.
Option C: Option C is incorrect — while rebound vasodilation between doses is part of the older conceptual model of analgesic rebound headache, the current understanding of MOH centers on central sensitization and receptor downregulation rather than simple vascular rebound. More importantly, switching to a longer-acting triptan does not treat established MOH; it only potentially shifts the timeline of the same overuse problem. The management must address withdrawal from the overused agent.
Option D: Option D is incorrect — ergotamine-related daily headache is not caused by cumulative cerebrovascular endothelial injury from chronic vasoconstrictive toxicity. The established mechanism of MOH is pharmacodynamic (central sensitization, receptor downregulation) rather than structural cerebrovascular damage, and niacin is not an established treatment for ergotamine-related MOH or for any cerebrovascular endothelial injury mechanism.

5. A 38-year-old man is admitted to an observation unit with a severe refractory migraine. The on-call resident initiates IV DHE 1 mg without any premedication, reasoning that the patient's nausea from the migraine itself has already resolved and that antiemetic pretreatment is therefore unnecessary. Within 30 minutes of the first DHE dose, the patient develops severe nausea and vomiting that limits his ability to continue the planned multi-dose protocol. Which of the following best explains why antiemetic pretreatment before IV DHE is standard practice and what was missed by omitting it?

A) Antiemetic pretreatment is required before IV DHE because DHE activates 5-HT3 receptors in the chemoreceptor trigger zone (CTZ), producing an acute emetic response that is specifically antagonized only by 5-HT3 blockers such as ondansetron; other antiemetic classes are ineffective for DHE-induced nausea because they do not block the relevant receptor subtype
B) Antiemetic pretreatment with metoclopramide or prochlorperazine is standard before IV DHE because IV administration produces a higher rate of nausea than intramuscular DHE, and both agents independently contribute to migraine relief through dopamine D2 receptor antagonism at the trigeminal nucleus caudalis (TNC) — making the pretreatment pharmacologically active against the migraine itself rather than merely supportive
C) Antiemetic pretreatment is required because DHE inhibits gastric motility by blocking dopamine D2 receptors in the gastric myenteric plexus, producing drug-induced gastroparesis that must be pre-empted by a prokinetic antiemetic; if given after IV DHE, metoclopramide is ineffective because DHE has already occupied all myenteric D2 receptors before the antiemetic arrives
D) Antiemetic pretreatment is needed because IV DHE crosses the blood-brain barrier rapidly and directly activates the area postrema (vomiting center) through 5-HT1D receptor agonism; the pretreatment with ondansetron or scopolamine specifically blocks area postrema 5-HT1D receptors and prevents the central emetic response before DHE reaches CNS concentrations
E) Antiemetic pretreatment is a precaution against allergic cross-reactivity between DHE and the ergot alkaloid components of common foods (such as rye bread); IV DHE can unmask food-related ergot sensitization and provoke mast cell degranulation in sensitized patients, producing nausea as part of a mild anaphylactoid response that antihistamines prevent

ANSWER: B

Rationale:

This question asked you to explain the rationale for antiemetic pretreatment before IV DHE and identify what was missed. IV DHE produces a higher incidence of nausea than intramuscular administration, making antiemetic pretreatment standard practice for the IV route. The standard agents are metoclopramide 10 mg IV or prochlorperazine 10 mg IV. The critical pharmacological insight is that both of these agents are not merely antiemetics in this context — they are dopamine D2 receptor antagonists that have independent direct antimigraine activity through antagonism at D2 receptors in the trigeminal nucleus caudalis (TNC), where dopaminergic neurons modulate trigeminal pain processing. This means antiemetic pretreatment contributes to headache relief as well as tolerability, making it a pharmacologically active component of the Raskin protocol rather than simply a supportive measure. By omitting pretreatment, the resident not only allowed predictable nausea to interrupt the protocol but also missed the opportunity to add an independent antimigraine mechanism to the treatment.

Option A: Option A is incorrect — DHE's nausea is not primarily mediated by 5-HT3 receptor activation in the CTZ, and ondansetron is not the standard antiemetic pretreatment for IV DHE. The standard agents are metoclopramide and prochlorperazine, chosen specifically because their D2 antagonism provides independent antimigraine benefit in addition to antiemetic effect. 5-HT3 antagonists lack the D2-mediated antimigraine activity that makes the standard pretreatment pharmacologically active against the migraine itself.
Option C: Option C is incorrect — DHE does not produce gastroparesis by blocking dopamine D2 receptors in the gastric myenteric plexus; this mechanism describes the rationale for metoclopramide's prokinetic action, not DHE's pharmacology. DHE does not occupy all gastric myenteric D2 receptors in a way that renders metoclopramide ineffective if given after DHE.
Option D: Option D is incorrect — IV DHE does not rapidly cross the blood-brain barrier to directly activate the area postrema through 5-HT1D receptor agonism. Blood-brain barrier penetration for DHE is limited under standard clinical conditions, and scopolamine is not the standard antiemetic pretreatment for IV DHE. The area postrema sits outside the blood-brain barrier, so direct activation is possible, but the mechanism involves dopaminergic stimulation, and the standard treatment is D2 antagonism, not 5-HT1D blockade.
Option E: Option E is incorrect — IV DHE does not cause nausea through allergic cross-reactivity with food-derived ergot alkaloids, and there is no established mechanism by which ergot food sensitization produces anaphylactoid nausea during IV DHE administration. The nausea from IV DHE is a direct pharmacological effect predictable from its receptor profile, not an immune-mediated response.

6. A 31-year-old woman with episodic migraine is admitted through the emergency department. She has had a continuous, debilitating migraine for 96 hours (4 days). During this time she has failed oral sumatriptan (taken on day 1), oral naproxen, oral metoclopramide, IV ketorolac given in the ED on day 2, and a single IV dose of prochlorperazine. She is nauseated, has been unable to maintain adequate oral intake, and is significantly functionally impaired. Her cardiovascular examination is normal, she is not pregnant, and she takes no medications associated with CYP3A4 inhibition. Which of the following represents the most appropriate next step in her pharmacological management?

A) Subcutaneous sumatriptan 6 mg, which provides the highest bioavailability and most rapid onset of any triptan formulation and should be effective for this patient since her prior oral sumatriptan failure on day 1 may have been attributable to migraine-associated gastroparesis impairing absorption rather than to a true pharmacodynamic treatment failure
B) IV valproate sodium 1000 mg infused over 15 minutes, which is the first-line agent for status migrainosus in current American Headache Society guidelines and has been demonstrated in randomized controlled trials to be superior to IV DHE for the acute management of prolonged refractory migraine through its sodium channel and GABA-enhancing mechanisms
C) Oral ergotamine-caffeine (Cafergot) 2 mg, which should now be effective since the gastroparesis that impaired her oral sumatriptan absorption on day 1 has resolved after 4 days, and the rectal suppository formulation should be reserved for patients who cannot swallow tablets
D) IV dihydroergotamine (DHE), administered as 0.5–1 mg IV every 8 hours with antiemetic pretreatment (metoclopramide or prochlorperazine 10 mg IV before each dose) for 2–3 days in an inpatient setting — the Raskin protocol — which is one of the most effective treatments for status migrainosus and provides sustained headache freedom that no comparable parenteral triptan sustained-dosing protocol can replicate
E) IV methylprednisolone 1000 mg daily for 3 days, which is the treatment of choice for status migrainosus in patients who have failed all acute migraine-specific agents including triptans and ergots, since corticosteroids break the central sensitization maintaining her pain by suppressing TNC neuroinflammation at the brainstem level

ANSWER: D

Rationale:

This question asked you to identify the appropriate treatment for status migrainosus — a debilitating migraine lasting more than 72 hours — in a patient who has failed multiple acute agents. This patient meets the definition of status migrainosus (continuous migraine for 96 hours), and IV DHE via the Raskin protocol is the treatment of choice. The protocol consists of IV DHE 0.5–1 mg every 8 hours for 2–3 days with antiemetic pretreatment before each dose (metoclopramide 10 mg IV or prochlorperazine 10 mg IV), administered in an inpatient or observation unit setting. This protocol achieves sustained headache freedom at 48–72 hours and is one of the most effective treatments for this condition. A critical distinguishing feature is that no comparable parenteral sustained-dosing protocol exists for triptans: subcutaneous or intranasal sumatriptan is used for individual attacks but not as a repeated scheduled inpatient dosing protocol for status migrainosus. This is the clinical niche where DHE's pharmacokinetic and pharmacodynamic profile — longer duration, active metabolites, multiday protocol feasibility — provides genuine therapeutic value that triptans cannot replicate.

Option A: Option A is incorrect — subcutaneous sumatriptan may be appropriate for individual migraine attacks with gastroparesis-related oral absorption failure, but for status migrainosus of 4 days' duration that has already failed an oral triptan and multiple other agents, a single dose of any triptan formulation is unlikely to provide the sustained headache freedom that the Raskin protocol achieves. Status migrainosus requires a sustained inpatient treatment approach, not a single-dose retry.
Option B: Option B is incorrect — IV valproate sodium is used as an adjunctive or rescue agent in status migrainosus management but is not established as first-line superior to IV DHE in current guidelines. The description of IV valproate as "first-line" and "demonstrated superior to IV DHE in randomized controlled trials" for status migrainosus overstates its evidence base and misrepresents the current standard of care.
Option C: Option C is incorrect — oral ergotamine is inappropriate for this patient. She is nauseated and unable to maintain oral intake, making oral drug administration unreliable; more importantly, for established status migrainosus of 4 days' duration, parenteral IV DHE is the indicated treatment. Oral ergotamine's poor bioavailability and the gastroparesis associated with prolonged migraine attacks make it inadequate for this clinical scenario.
Option E: Option E is incorrect — IV methylprednisolone 1 gram daily for 3 days (pulse corticosteroids) is used in some refractory headache protocols but is not established as the treatment of choice for status migrainosus ahead of IV DHE. Corticosteroids have a role in breaking prolonged migraine cycles and preventing early recurrence, but they are not the primary treatment for the acute pain of status migrainosus in this pharmacological hierarchy.

7. A 36-year-old man with episodic migraine calls his neurologist's office 3 hours into a severe migraine attack. He reports that in addition to the throbbing headache, his scalp has become tender — he cannot tolerate his glasses touching his temples and combing his hair feels painful. He asks whether he should now take the intranasal DHE that was prescribed for him. His neurologist recognizes the scalp tenderness as a specific clinical sign with important pharmacological implications. Which of the following correctly identifies the clinical significance of the scalp tenderness and its implication for expected DHE response?

A) The scalp tenderness represents cutaneous allodynia — a clinical marker of established central sensitization of the trigeminal nucleus caudalis (TNC) — indicating that second-order TNC neurons are now generating pain independently of peripheral trigeminal input; DHE acting peripherally at dural vessels and trigeminal terminals will be substantially less effective at this stage because the pain is no longer peripherally maintained, and earlier treatment would have produced a better response
B) The scalp tenderness represents peripheral sensitization of the greater occipital nerve from sustained CGRP-mediated dural inflammation, indicating that ergotamine plasma concentrations need to be doubled to achieve the receptor occupancy required to suppress the now-sensitized peripheral afferents; intranasal DHE at standard doses will be insufficient and parenteral DHE is required
C) The scalp tenderness is a sign of ergotamine-related cervical vasoconstriction reducing blood flow to the greater occipital nerve territory, indicating that this patient has underlying peripheral vascular disease affecting the posterior neck vasculature; DHE is preferred over ergotamine in this setting because its preferential venous vasoconstrictive activity spares the posterior cervical arterial circulation
D) The scalp tenderness represents meningeal irritation from CGRP-mediated dural plasma protein extravasation that has spread beyond the dura to involve the scalp pericranium; DHE should be administered immediately and will be highly effective at this stage because CGRP-mediated pericranial inflammation is the primary therapeutic target of 5-HT1D receptor agonism, which is most potent when the inflammatory process is actively spreading
E) The scalp tenderness is a normal feature of the migraine attack reflecting sympathetic activation causing scalp blood vessel vasoconstriction that reduces pericranial oxygen delivery; DHE at this stage will be more effective than at attack onset because DHE's venoconstriction increases venous return and reflexively reduces the sympathetic outflow causing the scalp ischemia

ANSWER: A

Rationale:

This question asked you to identify the clinical significance of scalp allodynia during a migraine attack and apply it to predict DHE response. Scalp tenderness — sensitivity to hair combing, glasses contact, or scalp palpation — is the clinical manifestation of cutaneous allodynia, which is the established clinical marker of central sensitization of the trigeminal nucleus caudalis (TNC). As a migraine attack progresses and sustained peripheral nociceptive input from sensitized dural trigeminal afferents reaches the TNC, second-order neurons in the TNC develop central sensitization: they become hyperexcitable and begin generating pain signals through intrinsic central activity, no longer depending on ongoing peripheral nociceptive drive to maintain their firing. Once allodynia is established (typically 2–4 hours into an attack in susceptible patients), peripheral interventions — ergots and triptans acting on dural vessels and trigeminal terminals — become substantially less effective because the pain is now centrally maintained. This does not mean DHE is completely ineffective, but the patient and clinician should have realistic expectations of a reduced response compared with what early treatment would have produced.

Option B: Option B is incorrect — scalp allodynia represents central sensitization, not peripheral sensitization of the greater occipital nerve from dural inflammation. The therapeutic implication is not that higher DHE doses are required to achieve peripheral receptor occupancy; it is that peripheral pharmacological interventions have reduced efficacy once pain is maintained by centrally sensitized neurons independent of peripheral input.
Option C: Option C is incorrect — scalp tenderness in the context of a migraine attack is cutaneous allodynia from central sensitization, not a sign of underlying peripheral vascular disease affecting cervical vessels. The greater occipital nerve territory tenderness during migraine reflects central sensitization spreading to involve thalamic and cortical pain processing, not vascular ischemia of posterior neck structures.
Option D: Option D is incorrect — scalp tenderness does not indicate active spread of CGRP-mediated dural inflammation to the pericranium, and DHE is not most potent at the stage when allodynia is established. The pharmacological implication of established allodynia is the opposite: DHE and triptans are less effective at this stage, not more effective, because central sensitization has shifted pain maintenance from peripheral to central mechanisms.
Option E: Option E is incorrect — scalp tenderness during migraine is not caused by sympathetic vasoconstriction reducing pericranial oxygen delivery, and allodynia does not indicate a stage at which DHE's baroreceptor-mediated sympathetic reduction would be particularly beneficial. The clinical significance of cutaneous allodynia is specifically its marking of the transition to centrally maintained pain that reduces peripheral pharmacological efficacy.

8. A 40-year-old woman with episodic migraine took one ergotamine-caffeine tablet (1 mg ergotamine) at 8 AM for a migraine attack and obtained partial relief. By 6 PM the same day (10 hours later), her headache has fully returned. She calls her neurologist's office asking whether she can now take sumatriptan 50 mg, since "the ergotamine has worn off" after 10 hours. The covering physician must advise her accurately. Which of the following is the correct response?

A) She may take sumatriptan now because 10 hours exceeds ergotamine's alpha-phase half-life of 2 hours by a factor of five, meaning that ergotamine plasma concentrations have been reduced to less than 3% of peak values, and the residual pharmacodynamic risk from ergotamine is pharmacokinetically negligible at this time point
B) She may take sumatriptan now because the ergot-triptan interaction is clinically relevant only when the two agents are taken within 4 hours of each other; beyond 4 hours, the additive vasoconstrictive risk is below the threshold for adverse cardiovascular outcomes based on the pharmacokinetic modeling used to establish the prescribing interval in the original FDA labeling
C) She must not take sumatriptan — a minimum of 24 hours must elapse after the last ergotamine dose before any triptan may be used; ergotamine's beta-phase half-life is approximately 21 hours and its active vasoconstrictive metabolites persist for 24 hours or more after a single dose, meaning that significant vasoconstrictive pharmacodynamic activity from the ergotamine remains present at 10 hours, and adding sumatriptan's 5-HT1B agonism would produce additive coronary and peripheral vasoconstriction
D) She may take sumatriptan now if she takes a lower dose (25 mg instead of 50 mg) to reduce the additive vasoconstrictive burden; the FDA-required 24-hour interval was established for full-dose triptan use, and a 50% dose reduction at the 10-hour mark provides sufficient pharmacokinetic margin to prevent clinically significant additive vasoconstriction
E) She must not take sumatriptan, but she may take a CGRP receptor antagonist (gepant) such as ubrogepant because gepants do not activate 5-HT1B receptors and therefore do not contribute to the additive vasoconstriction that makes the ergot-triptan combination dangerous; the 24-hour interval applies only to 5-HT1B/1D agonist triptans and not to mechanistically distinct antimigraine agents

ANSWER: C

Rationale:

This question asked you to apply the ergot-triptan combination prohibition and correct interval to a realistic clinical scenario. The patient must not take sumatriptan at 10 hours after ergotamine. The FDA-mandated minimum interval between any ergot-containing product and any triptan is 24 hours — not 10 hours, not 12 hours, and not adjustable by dose reduction. The pharmacokinetic reason this interval is necessary is precisely the point the patient has misunderstood: she is thinking only about the alpha-phase half-life of 2 hours (the distribution phase), which governs how quickly ergotamine distributes from plasma into tissues. But the pharmacodynamically relevant half-life is the beta-phase (elimination) half-life of approximately 21 hours, which governs how slowly ergotamine and its active vasoconstrictive metabolites are cleared from the body. At 10 hours post-dose, substantial ergotamine and active metabolite concentrations remain, and adding sumatriptan's 5-HT1B agonism at dural and coronary vessels would produce additive vasoconstriction with risk of coronary and peripheral arterial vasospasm. Some clinicians extend the interval to 48 hours given ergotamine's particularly long beta-phase half-life.

Option A: Option A is incorrect — the patient's reasoning that "the ergotamine has worn off" because more than five alpha-phase half-lives have elapsed is the pharmacokinetic error the question is designed to identify. The alpha-phase half-life governs distribution, not elimination; at 10 hours, the beta-phase (elimination) half-life of 21 hours means approximately 71% of the drug and its metabolites remain in the body, representing substantial residual vasoconstrictive activity.
Option B: Option B is incorrect — the FDA-mandated minimum interval between ergots and triptans is 24 hours, not 4 hours. There is no established 4-hour threshold based on pharmacokinetic modeling in the prescribing labeling; the 24-hour interval is the standard minimum required by FDA labeling for all ergot-containing products and all triptans.
Option D: Option D is incorrect — dose reduction of sumatriptan to 25 mg does not change the minimum required interval. The 24-hour interval is not a full-dose-specific requirement; it applies regardless of the triptan dose chosen, because the residual ergotamine and metabolite concentrations at 10 hours are not proportionally reduced by using a lower triptan dose.
Option E: Option E is incorrect — while it is true that CGRP receptor antagonists (gepants) do not activate 5-HT1B receptors and therefore do not carry the same additive vasoconstrictive risk as triptans when used after ergotamine, option E is not the most directly relevant answer to the patient's question about sumatriptan specifically. The question specifically asks whether she can take sumatriptan, and the correct answer must address the sumatriptan interval prohibition directly. Noting that gepants are an alternative is clinically useful but does not constitute the primary answer to whether sumatriptan is permitted at 10 hours.

9. A 29-year-old woman uses intranasal DHE (Migranal) successfully for her migraines throughout most of the year, typically achieving headache relief within 60–90 minutes. Each spring she develops moderate-to-severe seasonal allergic rhinitis with nasal congestion, mucosal edema, and rhinorrhea. She reports that during allergy season, her intranasal DHE "barely works" — relief is incomplete, onset is delayed to 3–4 hours if it occurs at all, and some attacks are not aborted. She asks whether the medication has lost its potency or whether she needs a higher dose. Which of the following most accurately explains her observation and identifies the most appropriate management adjustment?

A) Her intranasal DHE has lost potency because seasonal exposure to aeroallergens in high pollen seasons chemically degrades the DHE molecule through oxidative reactions with airborne reactive oxygen species that contaminate the nasal spray device; she should obtain a fresh supply of intranasal DHE at the start of each allergy season and store it in a sealed, humidity-controlled container
B) Her reduced response during allergy season reflects pharmacodynamic tolerance to intranasal DHE from year-round use; seasonal allergic rhinitis is a physiological stressor that accelerates 5-HT1B/1D receptor downregulation in the trigeminovascular system through histamine-mediated inflammatory pathways, making her trigeminal vasculature less responsive to the same DHE dose during symptomatic allergy seasons
C) Her reduced response reflects competition between DHE and histamine for 5-HT1B/1D receptors in dural vessels; histamine released during allergic rhinitis episodes activates H1 receptors on dural vascular smooth muscle that share a G-protein signaling pathway with 5-HT1B receptors, reducing DHE's effective receptor occupancy through downstream signal interference
D) Her reduced response reflects pharmacokinetic competition: cetirizine or loratadine antihistamines that she likely takes for her allergic rhinitis inhibit CYP3A4 activity in the liver, increasing DHE plasma concentrations but paradoxically reducing receptor sensitivity through excessive 5-HT1B receptor desensitization from supratherapeutic DHE exposure
E) Her intranasal DHE has not lost potency — the problem is reduced bioavailability caused by nasal mucosal edema and congestion from the allergic rhinitis, which decreases the absorption surface area and vascular permeability available for DHE uptake across the nasal mucosa; the appropriate management adjustment is to switch to intramuscular or intravenous DHE during allergy season, since these routes are not susceptible to nasal mucosal variability

ANSWER: E

Rationale:

This question asked you to apply the known pharmacokinetic vulnerability of intranasal DHE to a clinical scenario involving seasonal nasal pathology. Intranasal DHE achieves baseline bioavailability of approximately 32–40% of IV administration, and this bioavailability is highly sensitive to nasal mucosal status. Allergic rhinitis produces mucosal edema, congestion, and inflammatory changes that reduce the effective absorption surface area and alter vascular permeability in the nasal mucosa, leading to substantially reduced and more variable DHE absorption. This explains her observation precisely: incomplete relief, delayed onset (reflecting slower and lower-peak absorption), and treatment failures during congested periods. The drug has not lost its intrinsic potency — the pharmacological problem is at the route-of-administration level, not at the receptor level. The appropriate management is to switch to a route that bypasses nasal mucosal variability: intramuscular DHE during allergy season provides approximately the same bioavailability as intranasal under optimal conditions but without dependence on nasal mucosal status; IV DHE provides the most reliable plasma concentrations for severe attacks.

Option A: Option A is incorrect — intranasal DHE degradation by aeroallergen-associated reactive oxygen species is not an established pharmacokinetic mechanism. DHE stability in the nasal spray formulation is not meaningfully affected by seasonal air quality or allergen exposure. The pharmacokinetic problem is mucosal absorption impairment, not drug degradation.
Option B: Option B is incorrect — seasonal allergic rhinitis does not accelerate 5-HT1B/1D receptor downregulation through histamine-mediated inflammatory pathways in the trigeminovascular system. Pharmacodynamic tolerance to intranasal DHE from year-round use would present as reduced efficacy throughout the year, not specifically during allergy season. The seasonal pattern is the pharmacokinetic clue pointing to nasal mucosal absorption impairment.
Option C: Option C is incorrect — histamine does not share a G-protein signaling pathway with 5-HT1B receptors on dural vascular smooth muscle in a way that reduces DHE's effective receptor occupancy. H1 and 5-HT1B receptors are structurally distinct GPCRs with different downstream signaling; competitive downstream signal interference between histamine H1 and DHE 5-HT1B signaling is not the established pharmacological explanation for this observation.
Option D: Option D is incorrect — second-generation antihistamines such as cetirizine and loratadine are not clinically significant CYP3A4 inhibitors at standard doses and do not produce pharmacokinetic interactions with DHE through CYP3A4 inhibition. The premise that antihistamine use increases DHE plasma concentrations through enzyme inhibition is pharmacologically incorrect.

10. A 52-year-old woman is admitted to the ICU with bilateral hand ischemia. She has been taking ergotamine-caffeine for migraines for 3 years without incident. Ten days ago, her primary care physician prescribed clarithromycin for a sinus infection without reviewing her medication list. She now has cold, mottled, pulseless fingers bilaterally with absent Doppler signals. The admitting team stops ergotamine and clarithromycin, confirms the diagnosis of drug interaction-precipitated ergotism, and begins IV phentolamine. After 2 hours of adequate alpha-adrenergic blockade with phentolamine, Doppler signals remain absent and the fingers are still cold and mottled. The intensivist asks why phentolamine has been ineffective. Which of the following most accurately explains the inadequate response to phentolamine and identifies the next correct intervention?

A) Phentolamine is ineffective because the high ergotamine plasma concentrations present in this interaction competitively displace phentolamine from alpha-adrenergic receptors despite adequate dosing; the correct next intervention is phenoxybenzamine, a non-competitive (irreversible) alpha-adrenergic blocker whose covalent receptor binding cannot be displaced by high ergotamine concentrations
B) Phentolamine provides only partial reversal because it blocks the alpha-adrenergic component of ergot-induced vasoconstriction but does not address the 5-HT2A receptor-mediated component, which continues to drive vasoconstriction independently; the correct next intervention is to add IV nitroprusside and/or IV prostaglandin E1 (alprostadil), which act downstream of receptor activation to produce vasodilation regardless of which receptor mechanism is driving smooth muscle contraction
C) Phentolamine is ineffective because this patient's ergotism has progressed to irreversible structural arterial wall injury from sustained ischemia, and pharmacological vasodilators cannot restore flow through vessels with fixed structural damage; emergency surgical sympathectomy is required to abolish adrenergic tone in the affected extremities and maximize vasodilation
D) Phentolamine is ineffective because the ergotism is being maintained by platelet-derived serotonin released in response to ergotamine-induced endothelial injury; the correct next intervention is IV cyproheptadine (a 5-HT2A antagonist) to block the platelet serotonin mediating the persistent vasoconstriction rather than the ergotamine receptor mechanism
E) Phentolamine is ineffective because ergotamine's primary vasoconstrictive mechanism in peripheral vessels is 5-HT1B receptor agonism, not alpha-adrenergic receptor activation; phentolamine has no 5-HT1B blocking activity, and the correct next intervention is methysergide (a 5-HT1B/2 antagonist) administered intravenously to competitively antagonize ergotamine at the peripheral 5-HT1B receptors maintaining the vasoconstriction

ANSWER: B

Rationale:

This question asked you to identify why phentolamine alone is insufficient in ergotism and what additional therapy addresses the unblocked mechanism. Ergotamine produces peripheral vasoconstriction through two distinct receptor mechanisms: alpha-adrenergic receptor activation (blocked by phentolamine) and 5-HT2A receptor activation on vascular smooth muscle (not blocked by phentolamine). Phentolamine competitively antagonizes alpha-1 and alpha-2 adrenergic receptors, reversing the adrenergic component of vasoconstriction. However, sustained 5-HT2A receptor activation by ergotamine and its active metabolites continues independently of alpha-adrenergic blockade, maintaining vasoconstriction and ischemia. The solution is to add vasodilators that act downstream of receptor activation — independent of which receptor is activated — by directly relaxing vascular smooth muscle: IV nitroprusside (donates nitric oxide, activating soluble guanylate cyclase to produce cGMP-mediated smooth muscle relaxation) and/or IV prostaglandin E1 alprostadil (activates prostanoid receptors to produce cAMP-mediated smooth muscle relaxation). Both mechanisms bypass the unblocked 5-HT2A component entirely by acting at post-receptor effector levels. Heparin anticoagulation also remains important to prevent secondary thrombosis in severely ischemic vessels.

Option A: Option A is incorrect — phentolamine's failure is not attributable to competitive displacement by high ergotamine concentrations at alpha-adrenergic receptors. Phentolamine's own binding affinity for alpha receptors is sufficient to achieve blockade even in the presence of elevated ergotamine concentrations. The mechanistic gap is the 5-HT2A receptor component that phentolamine cannot address regardless of its dose or binding characteristics. Phenoxybenzamine would also fail to address the 5-HT2A component for the same reason.
Option C: Option C is incorrect — at 2 hours into treatment, irreversible structural arterial wall injury is not yet the established explanation for treatment failure in ergotism. The persistent vasoconstriction is pharmacodynamically maintained by the 5-HT2A receptor mechanism, not yet structural. Surgical sympathectomy is a consideration in refractory cases but is not the next pharmacological step when receptor-downstream vasodilators have not yet been tried.
Option D: Option D is incorrect — ergotism is not maintained by platelet-derived serotonin released in response to endothelial injury. The vasoconstriction is caused by direct receptor activation by ergotamine and its metabolites at alpha-adrenergic and 5-HT2A receptors on vascular smooth muscle. Cyproheptadine does have 5-HT2A antagonist activity but is not an established IV treatment for acute ergotism; the standard protocol uses downstream vasodilators rather than serotonin receptor antagonists.
Option E: Option E is incorrect — ergotamine's primary peripheral vasoconstrictive mechanism is not 5-HT1B receptor agonism. 5-HT1B receptors mediate the cranial vasoconstriction that is ergotamine's antimigraine mechanism; peripheral vasoconstriction in ergotism involves alpha-adrenergic and 5-HT2A receptor activation. Methysergide is not an established IV treatment for acute ergotism, and its use as a 5-HT1B antagonist in this context conflates the cranial and peripheral receptor pharmacology of ergot alkaloids.

11. A 44-year-old man with a 10-year history of episodic cluster headache presents during an active cluster period — he is experiencing 2–3 severe unilateral periorbital attacks per day, each lasting 45–90 minutes, with associated ipsilateral lacrimation, rhinorrhea, and partial ptosis. He has no cardiovascular disease and is not on any interacting medications. His current cluster period has been refractory to high-flow oxygen and subcutaneous sumatriptan has produced only partial relief. He asks his neurologist whether DHE might be useful for his condition. Which of the following most accurately describes DHE's role in cluster headache management?

A) DHE has no established role in cluster headache because cluster attacks are mediated by hypothalamic activation and parasympathetic pathway dysregulation rather than by trigeminovascular mechanisms; since DHE acts exclusively on the peripheral trigeminovascular system, it has no pharmacological target relevant to the hypothalamic-autonomic pathophysiology of cluster headache
B) DHE is contraindicated in cluster headache because cluster attacks involve unilateral cranial vasoconstriction as their primary pathophysiology, and adding ergot-mediated vasoconstriction to an already vasoconstrictive attack would worsen the attack by further reducing blood flow in the affected cranial territory
C) DHE has been studied in cluster headache but is less effective than sumatriptan for acute attack termination because DHE's slower time to peak concentration (30 minutes for IM vs. 10–12 minutes for subcutaneous sumatriptan) is pharmacokinetically inadequate for attacks that peak within 5–10 minutes; DHE is useful only when attacks are unusually prolonged (greater than 3 hours)
D) IV and IM DHE are effective treatments for acute cluster headache attacks and have a role in cluster headache prophylaxis in selected patients; DHE's indication in cluster headache is an evidence-based use that extends beyond migraine and represents a distinct clinical application where its parenteral formulations and extended pharmacodynamic duration provide value
E) DHE is effective for cluster headache only when administered intranasally via the Migranal formulation because the ipsilateral nasal congestion of cluster attacks creates a direct conduit for DHE delivery to the affected sphenopalatine ganglion, from which the drug diffuses locally to block parasympathetic activation — a mechanism not available to parenteral formulations

ANSWER: D

Rationale:

This question asked you to correctly characterize DHE's role in cluster headache management beyond its primary migraine indication. IV and IM DHE are effective treatments for acute cluster headache attacks, and DHE also has a role in cluster headache prophylaxis — particularly for the inpatient management of refractory cluster periods — in selected patients. This represents a genuine and evidence-based clinical indication distinct from migraine. Cluster headache, while pathophysiologically distinct from migraine (involving hypothalamic circadian rhythm dysregulation and trigeminal-autonomic reflex activation), shares trigeminovascular mechanisms that respond to 5-HT1B/1D agonism. DHE's effectiveness in cluster attacks is consistent with its mechanism of action at the peripheral trigeminovascular level. For this patient who has achieved only partial relief with subcutaneous sumatriptan during an active cluster period, IV or IM DHE represents a clinically rational alternative or adjunct, and the neurologist's familiarity with DHE's cluster headache indication is clinically relevant.

Option A: Option A is incorrect — cluster headache does involve trigeminovascular mechanisms in addition to hypothalamic and parasympathetic dysregulation, and DHE does have pharmacological targets relevant to cluster headache. The claim that DHE acts exclusively on peripheral trigeminovascular mechanisms and therefore has no target in cluster headache pathophysiology is incorrect; DHE's 5-HT1B/1D agonism at the peripheral trigeminovascular level provides a therapeutic mechanism relevant to the pain component of cluster attacks.
Option B: Option B is incorrect — cluster headache pathophysiology does not involve primary unilateral cranial vasoconstriction. The vascular changes in cluster headache are secondary to trigeminovascular and parasympathetic activation, and ergot-mediated vasoconstriction does not worsen cluster attacks by adding vasoconstriction to an already vasoconstrictive process. This describes a pharmacological relationship that does not reflect cluster headache biology.
Option C: Option C is incorrect — DHE's slower time to peak concentration relative to subcutaneous sumatriptan does not disqualify it from use in cluster headache, and the claim that DHE is useful only for attacks longer than 3 hours is not supported by the clinical evidence for its use in cluster headache. IM DHE produces measurable plasma concentrations within 15–20 minutes and has established efficacy in cluster attacks of typical duration.
Option E: Option E is incorrect — intranasal DHE is not the only effective formulation for cluster headache, and the mechanism described — local delivery to the sphenopalatine ganglion via nasal congestion pathways — is not the established pharmacological explanation for DHE's efficacy in cluster headache. Parenteral (IV, IM) DHE has the stronger evidence base for cluster headache treatment and prophylaxis.